Abstract: Antibodies that specifically bind to Macrophage Stimulating Protein (MSP) analogs are provided. In certain embodiments, these antibodies may be used, for example, to detect MSP analogs in tissues when such analogs are used therapeutically.

Abstract: MSP analogs which have increased heterodimer formation and enhanced biological activity compared recombinant MSP are provided. The analogs are constructed by substituting unpaired cysteine residues which may interfere with interchain disulfide bonding. DNA sequences encoding MSP analogs, vectors and host cells for the expresssion of MSP analogs, and pharmaceutical compositons are also provided. The analogs may be used to treat conditions treatable by MSP such as gastrointestinal or hematopoietic disorders.

Abstract: MSP analogs which have increased heterodimer formation and enhanced biological activity compared recombinant MSP are provided. The analogs are constructed by substituting unpaired cysteine residues which may interfere with interchain disulfide bonding. DNA sequences encoding MSP analogs, vectors and host cells for the expression of MSP analogs, and pharmaceutical compositions are also provided. The analogs may be used to treat conditions treatable by MSP such as gastrointestinal or hematopoietic disorders.

Abstract: This disclosure relates to a novel class of hydroxamic and carboxylic acid based matrix metalloproteinase inhibitor derivatives. The disclosure further relates to pharmaceutical compositions containing such compounds and to the use of such compounds and compositions in the treatment of matrix metalloproteinase induced diseases.

Abstract: This disclosure relates to a novel class of hydroxamic and carboxylic acid based matrix metalloproteinase inhibitor derivatives. The disclosure further relates to pharmaceutical compositions containing such compounds and to the use of such compounds and compositions in the treatment of matrix metalloproteinase induced diseases.

Abstract: Compounds having the structural formula ##STR1## wherein X is HONH or HO and especially wherein the carbon atom bearing CH.sub.2 R.sup.1 has the R-configuration, the carbon atom bearing CH.sub.2 R.sup.2 has the S-configuration, R.sup.1 is isopropyl, R.sup.2 is 3-indolyl, m is 2, n is 0, p is 2 and R.sup.3 and R.sup.4 taken alone are each methyl or R.sup.3 and R.sup.4 taken together with N are morpholino and pharmaceutically acceptable acid addition salts or solvates or acid addition salts-solvates thereof, which are matrix-metalloprotease inhibitors useful in treatment of disease in which matrix-metalloprotease promoted connective tissue remodelling is a causative factor, for example, rheumatoid arthritis and cancer, and a method of preparation and method of use thereof and methods of preparation of intermediates therefor are disclosed.